Skip to content

Comparison of Ultrasound-Guided Different Concentration-Volume Combinations of Ropivacaine for Superficial Cervical Plexus Block in Thyroid Surgery

Comparison of Ultrasound-Guided Different Concentration-Volume Combinations of Ropivacaine for Superficial Cervical Plexus Block in Thyroid Surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115534
Enrollment
Unknown
Registered
2025-12-28
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid diseases

Interventions

No nerve block (Control):Patients in this group will receive standard general anesthesia alone, without any superficial cervical plexus block.
Ropivacaine, High-Volume High-Concentration:Patients will receive an ultrasound-guided bilateral superficial cervical plexus block with 20 mL of 0.375% ropivacaine per side, in addition to standard ge
Ropivacaine, High-Volume Low-Concentration:Patients will receive an ultrasound-guided bilateral superficial cervical plexus block with 20 mL of 0.25% ropivacaine per side, in addition to standard gene
Ropivacaine, Low-Volume High-Concentration:Patients will receive an ultrasound-guided bilateral superficial cervical plexus block with 10 mL of 0.375% ropivacaine per side, in addition to standard gen

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–65 years. 2. American Society of Anesthesiologists (ASA) physical status I–II. 3. Scheduled to undergo total thyroidectomy or lobectomy with isthmusectomy under general anesthesia. 4. Willing to participate in the study and having provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy to ropivacaine or related anaesthetic drugs 2. Infection at the puncture site 3. Serious coagulation disorders. 4. Presence of uncontrolled severe cardiac, pulmonary, hepatic or renal diseases. 5. Pre-operative neurological deficit or cognitive impairment, MMSE score <=20, unable to cooperate with post-operative evaluation. 6. Inability to understand assessment scales such as QoR-15. 7. Pregnant or breastfeeding women. 8. Underwent surgery within the last 3 months; participated in another study within the last 30 days; 9. refuse to participate in this study. 10. ASA grade III or above

Design outcomes

Primary

MeasureTime frame
Quality of Recovery-15 score at postoperative day 1;

Secondary

MeasureTime frame
Postoperative pain intensity(Assessed using the Visual Analogue Scale);Total opioid consumption within 24 hours postoperatively;Time to first request for analgesia; Incidence and severity of postoperative nausea and vomiting;Complications related to superficial cervical plexus block;

Countries

China

Contacts

Public ContactHai Guo

The First Affiliated Hospital of Xinjiang Medical University

115173948@qq.com+86 152 7673 0030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026